keyword
MENU ▼
Read by QxMD icon Read
search

Nonsmall cell lung ca

keyword
https://www.readbyqxmd.com/read/29146734/humanized-mice-in-studying-efficacy-and-mechanisms-of-pd-1-targeted-cancer-immunotherapy
#1
Minan Wang, Li-Chin Yao, Mingshan Cheng, Danying Cai, Jan Martinek, Chong-Xian Pan, Wei Shi, Ai-Hong Ma, Ralph W De Vere White, Susan Airhart, Edison T Liu, Jacques Banchereau, Michael A Brehm, Dale L Greiner, Leonard D Shultz, Karolina Palucka, James G Keck
Establishment of an in vivo small animal model of human tumor and human immune system interaction would enable preclinical investigations into the mechanisms underlying cancer immunotherapy. To this end, non-obese diabetic (NOD).Cg-Prkdc(scid)IL2rg(tm1Wjl) /Sz (null; NSG) mice were transplanted with human (h)CD34(+) hematopoietic progenitor and stem cells, which leads to the development of human hematopoietic and immune systems [humanized NSG (HuNSG)]. HuNSG mice received human leukocyte antigen partially matched tumor implants from patient-derived xenografts [PDX; nonsmall cell lung cancer (NSCLC), sarcoma, bladder cancer, and triple-negative breast cancer (TNBC)] or from a TNBC cell line-derived xenograft (CDX)...
November 16, 2017: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
https://www.readbyqxmd.com/read/29142404/chalepin-a-compound-from-ruta-angustifolia-l-pers-exhibits-cell-cycle-arrest-at-s-phase-suppresses-nuclear-factor-kappa-b-nf-%C3%AE%C2%BAb-pathway-signal-transducer-and-activation-of-transcription-3-stat3-phosphorylation-and-extrinsic-apoptotic-pathway-in-non-small-cell
#2
Jaime Stella Moses Richardson, Norhaniza Aminudin, Sri Nurestri Abd Malek
Background: Plants have been a major source of inspiration in developing novel drug compounds in the treatment of various diseases that afflict human beings worldwide. Ruta angustifolia L. Pers known locally as Garuda has been conventionally used for various medicinal purposes such as in the treatment of cancer. Objective: A dihydrofuranocoumarin named chalepin, which was isolated from the chloroform extract of the plant, was tested on its ability to inhibit molecular pathways of human lung carcinoma (A549) cells...
October 2017: Pharmacognosy Magazine
https://www.readbyqxmd.com/read/29141962/personalised-medicine-for-nonsmall-cell-lung-cancer
#3
Céline Mascaux, Pascale Tomasini, Laurent Greillier, Fabrice Barlesi
After years of standard care prescribed to cancer patients without any selection except the primary site and histology of the tumour, the era of precision medicine has revolutionised cancer care. Personalised medicine refers to the selection of patients for specific treatment based on the presence of specific biomarkers which indicate sensitivity to corresponding targeted therapies and/or lower toxicity risk, such that patients will have the greatest chance of deriving benefit from the treatments. Here, we review personalised medicine for nonsmall cell lung cancer...
December 31, 2017: European Respiratory Review: An Official Journal of the European Respiratory Society
https://www.readbyqxmd.com/read/29116937/synthesis-and-biological-evaluation-of-acyl-derivatives-of-hydroxyflavones-as-potent-antiproliferative-agents-against-drug-resistance-cell-lines
#4
Monika Stompor, Marta Świtalska, Joanna Wietrzyk
The synthesis of hydroxyflavone derivatives is described. The acyl derivatives of 3-, 6-, 7-hydroxyflavones (compounds 2, 4, 6, respectively) and chrysin (5,7-dihydroxyflavone, 7) were obtained in high yields and evaluated in vitro for their cytotoxic activity against several cancer cell lines of different origin: MCF-7 (breast cancer), A549 (nonsmall cell lung cancer), MES-SA (uterine sarcoma), LoVo (colon cancer), drug-resistant human cancer cells (MES-SA/DX5, LoVo/DX) and also towards non-cancer cell line MCF-10A (normal breast epithelial cells)...
November 8, 2017: Zeitschrift Für Naturforschung. C, A Journal of Biosciences
https://www.readbyqxmd.com/read/29109628/intraoperative-use-of-dexmedetomidine-is-associated-with-decreased-overall-survival-after-lung-cancer-surgery
#5
Juan P Cata, Vinny Singh, Brenda M Lee, John Villarreal, John R Mehran, J Yu, Vijaya Gottumukkala, Hagar Lavon, Shamgar Ben-Eliyahu
Background and Aims: The aim is to evaluate the association between the use of intraoperative dexmedetomidine with an increase in recurrence-free survival (RFS) and overall survival (OS) after nonsmall cell lung cancer (NSCLC) surgery. Material and Methods: This was a propensity score-matched (PSM) retrospective study. Single academic center. The study comprised patients with Stage I through IIIa NSCLC. Patients were excluded if they were younger than 18 years. Primary outcomes of the study were RFS and OS...
July 2017: Journal of Anaesthesiology, Clinical Pharmacology
https://www.readbyqxmd.com/read/29098170/interobserver-variability-in-tumor-contouring-affects-the-use-of-radiomics-to-predict-mutational-status
#6
Qiao Huang, Lin Lu, Laurent Dercle, Philip Lichtenstein, Yajun Li, Qian Yin, Min Zong, Lawrence Schwartz, Binsheng Zhao
Radiomic features characterize tumor imaging phenotype. Nonsmall cell lung cancer (NSCLC) tumors are known for their complexity in shape and wide range in density. We explored the effects of variable tumor contouring on the prediction of epidermal growth factor receptor (EGFR) mutation status by radiomics in NSCLC patients treated with a targeted therapy (Gefitinib). Forty-six early stage NSCLC patients (EGFR mutant:wildtype = 20:26) were included. Three experienced radiologists independently delineated the tumors using a semiautomated segmentation software on a noncontrast-enhanced baseline and three-week post-therapy CT scan images that were reconstructed using 1...
January 2018: Journal of Medical Imaging
https://www.readbyqxmd.com/read/29096940/anti-pd1-pdl1-induced-psoriasis
#7
Dimitra Voudouri, Vasiliki Nikolaou, Konstantinos Laschos, Andriani Charpidou, Nikolaos Soupos, Ioanna Triantafyllopoulou, Ioanna Panoutsopoulou, Gerasimos Aravantinos, K Syrigos, A Stratigos
BACKGROUND: Immune checkpoint inhibitors are novel agents approved for the treatment of late-stage malignancies. Despite its important clinical benefits, checkpoint inhibition is associated with a unique spectrum of side effects known as immune-related adverse events. Skin toxicities are the most frequent immune-related adverse events during anti-PD1 blockade therapies. Among them, rare cases of psoriasis exacerbation have been reported. METHODS: We present the clinical characteristics of exacerbated psoriasis in 5 patients under anti-PD1/PDL1 therapy...
October 18, 2017: Current Problems in Cancer
https://www.readbyqxmd.com/read/29095271/immune-related-adverse-events-associated-with-pd-1-and-pd-l1-inhibitors-for-nonsmall-cell-lung-cancer-protocol-for-a-systematic-review-and-meta-analysis
#8
REVIEW
Xiaoying Sun, Raheleh Roudi, Shangya Chen, Bin Fan, Hong Jin Li, Min Zhou, Xin Li, Bin Li
INTRODUCTION: Nonsmall cell lung cancer accounts for approximately 80% of all lung cancers, and approximately 75% of cases are diagnosed in the middle and late stages of disease. Unfortunately, limited treatment does not improve the prognosis of advanced disease. Monoclonal antibodies targeting programmed cell death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1) represent a new treatment paradigm for nonsmall cell lung cancer. Nevertheless, the immune-related adverse events (irAEs) associated with PD-1 and PD-L1 inhibitors are unique, and early recognition and treatment of these events are essential...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29070578/is-mitochondrial-dysfunction-a-driving-mechanism-linking-copd-to-nonsmall-cell-lung-carcinoma
#9
REVIEW
Francois Ng Kee Kwong, Andrew G Nicholson, Celeste L Harrison, Philip M Hansbro, Ian M Adcock, Kian Fan Chung
Chronic obstructive pulmonary disease (COPD) patients are at increased risk of developing nonsmall cell lung carcinoma, irrespective of their smoking history. Although the mechanisms behind this observation are not clear, established drivers of carcinogenesis in COPD include oxidative stress and sustained chronic inflammation. Mitochondria are critical in these two processes and recent evidence links increased oxidative stress in COPD patients to mitochondrial damage. We therefore postulate that mitochondrial damage in COPD patients leads to increased oxidative stress and chronic inflammation, thereby increasing the risk of carcinogenesis...
December 31, 2017: European Respiratory Review: An Official Journal of the European Respiratory Society
https://www.readbyqxmd.com/read/29069017/lymph-node-dissection-and-survival-in-patients-with-early-stage-nonsmall-cell-lung-cancer-a-10-year-cohort-study
#10
Yang Shen-Tu, Feng Mao, Yan Pan, Wenli Wang, Liang Zhang, Hui Zhang, Baijun Cheng, Haifa Guo, Zhiqiang Wang
It is still debatable whether complete mediastinal lymph node dissection (MLND) is associated with better survival than mediastinal lymph node sampling (MLNS) in surgical treatment of nonsmall cell lung cancer (NSCLC). We aimed to assess the impact of lymph node dissection on long-term survival among stage I NSCLC patients.In this cohort study, 317 stage I NSCLC Chinese patients in Shanghai Chest Hospital were followed up for at least 10 years to evaluate the impact of different lymph node dissection modes on their survival...
October 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29067858/immune-related-intestinal-pseudo-obstruction-associated-with-nivolumab-treatment-in-a-lung-cancer-patient
#11
Georgios Fragulidis, Eirini Pantiora, Vasiliki Michalaki, Elissaios Kontis, Elias Primetis, Antonios Vezakis, Andreas Polydorou
Immune checkpoint inhibition therapy using targeted monoclonal antibodies is a new therapeutic approach with significant survival benefit for patients with several cancer types. However, their use can be associated with unique immune-related adverse effects as a consequence of impaired self-tolerance due to loss of T-cell inhibition via a nonselective activation of the immune system. Nivolumab is an anti-PD-1 immune checkpoint inhibitor that was recently developed for cancer immunotherapy with remarkable responses in nonsmall cell lung cancer patients...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29038154/deactivated-crispr-associated-protein-9-for-minor-allele-enrichment-in-cell-free-dna
#12
Amin Aalipour, Jonathan C Dudley, Seung-Min Park, Surya Murty, Jacob J Chabon, Evan A Boyle, Maximilian Diehn, Sanjiv S Gambhir
BACKGROUND: Cell-free DNA (cfDNA) diagnostics are emerging as a new paradigm of disease monitoring and therapy management. The clinical utility of these diagnostics is relatively limited by a low signal-to-noise ratio, such as with low allele frequency (AF) mutations in cancer. While enriching for rare alleles to increase their AF before sample analysis is one strategy that can greatly improve detection capability, current methods are limited in their generalizability, ease of use, and applicability to point mutations...
October 16, 2017: Clinical Chemistry
https://www.readbyqxmd.com/read/29033676/the-role-of-fluorodeoxy-d-glucose-positron-emission-tomography-computed-tomography-in-nodal-staging-of-nonsmall-cell-lung-cancer-in-sequential-surgical-algorithm
#13
Yuyang Zhang, Yolanda Elam, Patricia Hall, Hadyn Williams, Darko Pucar, Vijay Patel
With nonsmall cell lung cancer (NSCLC), accurate mediastinal nodal staging is crucial to determine whether a patient is or is not a surgical candidate. Traditionally, computed tomography (CT) and fluorodeoxy-D-glucose (FDG) positron emission tomography (PET)/CT are the initial steps followed by tissue sampling through mediastinoscopy and/or thoracotomy, which are invasive procedures. There is controversy regarding the possibility of omission of the invasive diagnostic procedures and solely relying on noninvasive presurgical staging CT and FDG PET/CT results...
October 2017: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/29024297/reducing-dose-to-the-lungs-through-loosing-target-dose-homogeneity-requirement-for-radiotherapy-of-non-small-cell-lung-cancer
#14
Junjie Miao, Hui Yan, Yuan Tian, Pan Ma, Zhiqiang Liu, Minghui Li, Wenting Ren, Jiayun Chen, Ye Zhang, Jianrong Dai
It is important to minimize lung dose during intensity-modulated radiation therapy (IMRT) of nonsmall cell lung cancer (NSCLC). In this study, an approach was proposed to reduce lung dose by relaxing the constraint of target dose homogeneity during treatment planning of IMRT. Ten NSCLC patients with lung tumor on the right side were selected. The total dose for planning target volume (PTV) was 60 Gy (2 Gy/fraction). For each patient, two IMRT plans with six beams were created in Pinnacle treatment planning system...
October 11, 2017: Journal of Applied Clinical Medical Physics
https://www.readbyqxmd.com/read/28980429/metabolic-characteristics-of-programmed-cell-death-ligand-1-expressing-lung-cancer-on-18-f-fluorodeoxyglucose-positron-emission-tomography-computed-tomography
#15
Kazuki Takada, Gouji Toyokawa, Tatsuro Okamoto, Shingo Baba, Yuka Kozuma, Taichi Matsubara, Naoki Haratake, Takaki Akamine, Shinkichi Takamori, Masakazu Katsura, Fumihiro Shoji, Hiroshi Honda, Yoshinao Oda, Yoshihiko Maehara
Programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) have been identified as novel targets of immunotherapy of lung cancer. In present study, we evaluated the metabolic characteristics of lung cancer by using (18) F-fluorodeoxyglucose positron emission tomography/computed tomography ((18) F-FDG PET/CT) with regard to PD-L1 protein expression. PD-L1 protein expression was evaluated by immunohistochemistry with the antibody clone SP142 in 579 surgically resected primary lung cancer patients...
November 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28968265/diagnostic-utility-of-pd-l1-expression-in-lung-adenocarcinoma-immunohistochemistry-and-rna-in-situ-hybridization
#16
Mohamad Mazen Gafeer, Kareem Hosny Mohammed, Claudia Ormenisan-Gherasim, Fahad Choudhary, Momin T Siddiqui, Cynthia Cohen
BACKGROUND: Programmed death receptor and programmed death ligand (PD-L1) are immunoregulatory proteins. Nonsmall cell lung cancer bypasses the immune system through the induction of protumorigenic immunosuppressive changes. The better understanding of immunology and antitumor immune responses has brought the promising development of novel immunotherapy agents like programmed death receptor checkpoint inhibitors. The aim of this study was to investigate the expression of PD-L1 in lung adenocarcinoma (ADC), comparing 2 different technologies: immunohistochemistry (IHC) by 2 methods versus RNA in situ hybridization (RISH)...
September 29, 2017: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/28958256/metastases-to-the-breast-from-nonsmall-cell-lung-carcinoma
#17
Celia Y Quang, Scott G Blair, Scott B Patterson, Sharla G Patterson
No abstract text is available yet for this article.
September 1, 2017: American Surgeon
https://www.readbyqxmd.com/read/28953659/clinicopathological-radiographic-and-oncogenic-features-of-primary-pulmonary-enteric-adenocarcinoma-in-comparison-with-invasive-adenocarcinoma-in-resection-specimens
#18
Long Zhao, Shanshan Huang, Jinjun Liu, Juan Zhao, Qiang Li, Huo-Qiang Wang
Primary pulmonary enteric adenocarcinoma (PEAC) is a rare subtype of primary lung adenocarcinoma. However, it is not known whether there are any distinctive clinical or molecular features.PEACs were retrospectively identified in 28 patients from July 2014 to June 2016. We compared the clinicopathological, radiographic, and oncogenic characteristics of PEAC and primary pulmonary invasive adenocarcinoma (IAC).A total of 28 PEAC patients and 92 IAC patients were compared. PEAC occurred more frequently in males (P = ...
September 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28953040/novel-therapeutic-agents-in-the-management-of-brain-metastases
#19
Vyshak A Venur, Manmeet S Ahluwalia
PURPOSE OF REVIEW: This review aims to highlight the novel therapeutic agents in the management of brain metastases which are in various stages of clinical development. We review the results from recent clinical trials, publications and presentations at recent national and international conferences. RECENT FINDINGS: Several new systemic treatment options for brain metastases are in early or advanced clinical trials. These drugs have good intracranial and extracranial activities...
August 4, 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/28901317/k-ras-mutation-and-resistance-to-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitor-treatment-in-patients-with-nonsmall-cell-lung-cancer
#20
Bin Zhou, Congrong Tang, Jie Li
OBJECTIVE: The aim of this study was to evaluate the relationship between k-RAS gene mutation and the resistance to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with nonsmall-cell lung cancer (NSCLC). METHODS: Forty-five pathologies confirmed NSCLC patients who received EGFR-TKI (Gefitinib) treatment were retrospectively included in this study. The mutation of codon 12 and 13, located in exon1 and exon 2 of k-RAS gene were examined by polymerase chain reaction (PCR) and DAN sequencing in tumor samples of the included 45 NSCLC patients...
2017: Journal of Cancer Research and Therapeutics
keyword
keyword
13799
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"